Research Questions:
1. What are the pathogenic mechanisms underlying cognitive impairment in chronic kidney disease (CKD) and dialysis patients?
2. How do serum biomarkers, proteomics, and metabolomics correlate with cognitive in CKD and dialysis patients?
3. Can an integrated model using clinical, omics, and neuroimaging data predict cognitive decline risk in CKD and dialysis patients?
Objectives:
1. Identify molecular biomarkers and biological pathways linking CKD and dialysis with cognitive impairment.
2. Analyze neuroimaging changes in brain regions affected by cognitive impairment in CKD and dialysis patients
3. Develop a predictive model integrating clinical, biomarker, and imaging data for early risk stratification of cognitive impairment in CKD and dialysis patients.
Scientific Rationale:
CKD and dialysis are associated with an increased risk of cognitive impairment, but the underlying mechanisms are not fully understood. A comprehensive understanding of the molecular and physiological changes in these patients could lead to the identification of novel therapeutic targets and improve patient outcomes. Integrating health-related data with multi-omics approaches, along with brain imaging, can provide a holistic view of the disease processes and aid in the development of accurate predictive models.